Product Details

Introduction:

Hexinor 5 mg, manufactured by Beacon Pharmaceuticals Ltd and supplied by Makkaa Pharma, is a potent anticholinergic medication designed to manage severe symptoms of Parkinson’s disease and to control drug-induced extrapyramidal symptoms (EPS). Containing Trihexyphenidyl HCl, Hexinor 5 mg effectively reduces muscle stiffness, tremors, and other motor symptoms associated with Parkinson’s disease, providing substantial relief for patients. This higher-dose formulation is particularly suited for individuals requiring stronger symptom control, enhancing their ability to manage daily activities and improving their overall quality of life.

Manufacturing Excellence of Beacon Pharmaceuticals Ltd.:

Beacon Pharmaceuticals Ltd. is committed to producing high-quality pharmaceutical products that meet stringent international standards. The development of Hexinor 5 mg reflects Beacon’s dedication to advancing neurological treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Hexinor 5 mg is a reliable and effective option for managing more severe symptoms of Parkinson’s disease and EPS.

Mechanism of Action:

Hexinor 5 mg contains Trihexyphenidyl HCl, an anticholinergic agent that works by inhibiting the action of acetylcholine, a neurotransmitter involved in muscle control. In Parkinson’s disease, there is an imbalance between dopamine and acetylcholine, leading to symptoms such as muscle rigidity, tremors, and bradykinesia (slowness of movement). By blocking acetylcholine receptors, Trihexyphenidyl helps restore the balance between these neurotransmitters, reducing the severity of Parkinson’s symptoms and improving motor function. Hexinor 5 mg is also highly effective in managing drug-induced extrapyramidal symptoms, providing relief from involuntary muscle movements and rigidity caused by antipsychotic medications.

Clinical Applications:

Hexinor 5 mg is indicated for the treatment of:

• Severe Parkinson’s Disease Symptoms: Hexinor is used to manage severe symptoms of Parkinson’s disease, including muscle stiffness, tremors, and bradykinesia, offering patients significant relief and improved motor control.
• Extrapyramidal Symptoms (EPS): Hexinor 5 mg is effective in treating severe drug-induced EPS, such as dystonia, akathisia, and Parkinsonism, often caused by the use of antipsychotic medications.

Clinical studies have demonstrated that Trihexyphenidyl HCl is highly effective in reducing the severity of Parkinson’s symptoms and managing EPS, providing patients with substantial symptom relief and improved quality of life.

Dosage and Administration:

The recommended dosage of Hexinor 5 mg depends on the severity of the condition and the patient’s response to treatment. The initial dose is typically low, with gradual increases to minimize side effects and achieve the desired therapeutic effect. Hexinor 5 mg is usually taken two to four times daily, as prescribed by a healthcare provider. The tablet should be swallowed whole with water, and it can be taken with or without food. It is important for patients to follow their healthcare provider’s instructions closely and to undergo regular monitoring to assess the effectiveness of the treatment and to make any necessary dosage adjustments.

Benefits of Hexinor 5 mg:

• High-Dose Symptom Relief: Hexinor 5 mg provides potent relief from severe symptoms of Parkinson’s disease, including tremors, muscle stiffness, and bradykinesia, helping patients maintain better motor function.
• Effective EPS Management: Hexinor 5 mg is highly effective in controlling severe extrapyramidal symptoms caused by antipsychotic medications, improving patient comfort and reducing side effects.
• Improved Quality of Life: By reducing the severity of Parkinson’s symptoms and EPS, Hexinor 5 mg significantly enhances the quality of life for patients, allowing them to perform daily activities more easily.
• Customizable Dosing: The higher dose of Hexinor 5 mg allows for tailored dosing to meet the specific needs of patients with severe symptoms, ensuring effective management of their condition.

Supplier: Makkaa Pharma

Makkaa Pharma ensures that Hexinor 5 mg is readily available to healthcare providers and patients, offering reliable access to this essential medication for managing severe Parkinson’s disease symptoms and drug-induced EPS. Their commitment to efficient supply and distribution supports effective treatment and improved outcomes for patients dealing with these challenging conditions.

Conclusion:

Hexinor 5 mg (Trihexyphenidyl HCl) by Beacon Pharmaceuticals Ltd, supplied by Makkaa Pharma, represents a significant advancement in the management of severe Parkinson’s disease and drug-induced extrapyramidal symptoms. This high-dose medication provides powerful relief from symptoms such as tremors, muscle stiffness, and bradykinesia, significantly improving the quality of life for patients. By incorporating Hexinor into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing these conditions, ultimately enhancing their overall well-being and daily functioning